12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IV Erwinaze: Phase I started

Jazz began an open-label, North American Phase I trial to evaluate 25,000 IU/m 2 IV Erwinaze thrice weekly in up to 25 ALL patients ages 1-30 years. A muscular injection formulation of Erwinaze is approved in the U.S., Canada, U.K. and several EU member...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >